Abstract: The present invention provides a radioisotope generator system with enhanced safety features and implements such system. In particular, the present invention provides a radioisotope generator system comprising a surface that comprises three ports: an evacuation port, a loading port, and a saline flush port. The saline flush port is permanently connected with the loading port so that the rinsing solution can be placed on the saline port and pass it through the Mo-99 vial to minimize the wastage of the Mo-99. The present invention provides a robust design of the three-port radioisotope generator, which is cost-effective and ensures improved safety from needle contamination.

Abstract: The embodiments of the present invention disclose a conjugate compound of formula X-J-MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof, preferably the invention relates to radiopharmaceutical compositions of 99mTc. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio-distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use.

Abstract: The present invention provides a closed loop generation and/or infusion system comprising a radionuclide generator, an activity detector, a controller, a dose calibrator, a pump, eluant source and an automated elution system controlled by software and hardware for generation and infusion of a radionuclide for administering a dose of generated radionuclide into a subject for diagnosing a peripheral arterial disease in a subject suffering from or suspected of suffering from peripheral arterial disease and/or metabolic disease via Positron Emitting Tomography (PET) or Single-photon emission computed tomography (SPECT) imaging technologies.

Abstract: The present invention provides a conjugate compound comprising a nanoparticulated enhanced permeability and retention (EPR) agent, which is an albumin, conjugated with one or more chelating agents, one or more target specific ligands and one or more detectable agents and optionally comprising one or more heterobifunctional crosslinkers and one or more pharmaceutically acceptable therapeutic agents. Further, the present invention provides a radiopharmaceutical composition and a kit comprising the said conjugate and also provides application of the same in diagnosis and therapy of various disease like cancer.

Abstract: The invention discloses to radiopharmaceutical composition of Fluorine-18 (F18) labelled styrylpyridine compounds, preferably F18 Florbetapir, that are free of undesirable nitrosamine drug substance related impurities (NDSRI) and other undesirable nitrosamine impurities. The disclosed radiopharmaceutical composition is used as a medicament for the treatment or diagnosis of a disease or condition associated with build-up of amyloid-? (A?) aggregates.

Abstract: Present invention relates to safety features for radiopharmaceutical dispensing system, wherein dispensing system comprises a controller, a source of radiopharmaceutical and other components. The controller is configured to perform automated quality control of the system to ensure that the system complies quality control before radioactive dose dispensing. The quality control comprises scanning the dispensing system, network or connected devices for an unauthorized connection, malware and ensure that system is free of any such cybersecurity threat before dispensing a radioactive dose.

Abstract: The present invention relates to a medical radioisotope transport system that securely holds the radiopharmaceutical imaging system or medical elution system to the floor of a vehicle and ensures the protection of the elution system during transportation. The transport system as per the present invention includes at least a floor-mounting device, a support mechanism with transportation plates, and a locking device. The transport system as per the present invention is encompassed with advanced technical and safety features to ensure safe transportation of radiopharmaceuticals ensuring compliance to the regulatory and quality requirements. The transport system as per the present invention is easy to use, and successfully overcome all the complexities involved in prior available methods for transportation of radiopharmaceutical imaging systems or medical radioisotope elution systems.

Abstract: The present invention relates to a theranostic delivery system or radiopharmaceutical drugs delivery system (100) with movable ergonomic workstation (3) having handles on the side(s) to move the cart. The radiopharmaceutical drugs delivery system (100) comprises of simple design and multiple enhanced safety features for user. The delivery system (100) includes a disposable secondary containment system (2) that protect the core workstation from contamination, a configurable dose transporter (6) that allows for safe transport of the hot dose between the hot lab to the infusion site and a disposable sealed fluid cartridge (7) to withdraw custom volume from the vial or syringe. The delivery system (100) comprises a theranostic informatics management system with a computer screen (19) as graphical user interface (GUI) with retractable rotating arm (20) to receive the various patient infusion parameters and effectively manage delivery of desired dose to patient.

Abstract: The invention provides an image processing method to assess quantitative myocardial blood flow and/or myocardial flow reserve, comprising the steps of: (a) pre-processing of images comprises: (i) reconstructing dynamic cine 3D tomographic myocardial perfusion imaging (MPI) data, (ii) optionally, denoising to improve the quality of image, (iii) extracting blood input function from a region of interest (ROI) of the left ventricle blood cavity, (iv) estimating the distribution volume (DV), given by the ratio of uptake and washout rates (K1/k2) to stabilize and improve estimation of K1, k2 and total blood volume (TBV) and subsequent myocardial blood flow measures, and (v) data normalization by dividing by the maximum of the blood input function; (b) assessing the individual signals pre-processed in step (a) to generate K1 and TBV parametric maps using artificial neural network; (c) post-processing of K1, k2 and TBV parametric maps; and of rest and stress myocardial blood flow to estimate myocardial flow reserve (

Abstract: The present invention relates to a theranostic delivery system or radiopharmaceutical drugs delivery system (100) with movable ergonomic workstation (3) having handles on the side(s) to move the cart. The radiopharmaceutical drugs delivery system (100) comprises of simple design and multiple enhanced safety features for user. The delivery system (100) includes a disposable secondary containment system (2) that protect the core workstation from contamination, a configurable dose transporter (6) that allows for safe transport of the hot dose between the hot lab to the infusion site and a disposable sealed fluid cartridge (7) to withdraw custom volume from the vial or syringe. The delivery system (100) comprises a theranostic informatics management system with a computer screen (19) as graphical user interface (GUI) with retractable rotating arm (20) to receive the various patient infusion parameters and effectively manage delivery of desired dose to patient.

Abstract: The embodiments of the present invention disclose a conjugate compound of formula X-J-MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio-distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use.

Abstract: The present invention relates to a pharmaceutical cold kit composition comprising a chelating agent linked to somatostatin receptor binding organic moiety, a stabilizer, a buffer, and a caking agent or bulking agent, wherein the composition is free of sequestering agent. Further, the present invention also relates to the process of preparing reconstituted or radiolabeled solution composition having high in use stability and radiochemical purity and use thereof for diagnostic and/or therapeutic purposes.

Abstract: The embodiments of the present invention disclose a conjugate compound of formula X-J-MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof, preferably the invention relates to radiopharmaceutical compositions of 99mTc. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio-distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use.

Abstract: The present invention provides an image processing method to assess quantitative myocardial blood flow and/or myocardial flow reserve, comprising the steps of: (a) pre-processing of images comprises: (i) reconstructing dynamic cine 3D tomographic myocardial perfusion imaging (MPI) data, (ii) optionally, denoising to improve the quality of image, (iii) extracting blood input function from a region of interest (ROI) of the left ventricle blood cavity, (iv) estimating the distribution volume (DV), given by the ratio of uptake and washout rates (K1/k2) to stabilize and improve estimation of K1, k2 and total blood volume (TBV) and subsequent myocardial blood flow measures, and (v) data normalization by dividing by the maximum of the blood input function; (b) assessing the individual signals pre-processed in step (a) in order to generate K1 and TBV parametric maps using artificial neural network; (c) post-processing of K1, k2 and TBV parametric maps; and of rest and stress myocardial blood flow to estimate myocardi

Abstract: The present invention describes methods and techniques to improve scintigraphic images obtained by using nuclear medicine techniques for diagnostic analysis. The present invention describes a method and technique to up-sample and down-sample nuclear medicine images that models photon counts and noise characteristics of an image at its target resolution.

Abstract: The invention is a theranostic delivery system or radiopharmaceutical drugs delivery system with movable workstation having handles. The workstation of theranostic delivery system or radiopharmaceutical drugs delivery system also has an on-board shielded disposal system for waste collection, which is operated by foot actuated system for locked and unlocked modes during the device journey. The theranostic delivery system or radiopharmaceutical drugs delivery system comprises a status light system that illuminates the working area to enable distance monitoring. Further, the delivery system includes a disposable secondary containment system that protects the core workstation from contamination, a configurable dose transporter and a disposable sealed fluid cartridge to withdraw custom volume from the vial or syringe.

Abstract: The invention is a theranostic delivery system or radiopharmaceutical drugs delivery system with movable workstation having handles. The workstation of theranostic delivery system or radiopharmaceutical drugs delivery system also has an on-board shielded disposal system for waste collection, which is operated by foot actuated system for locked and unlocked modes during the device journey. The theranostic delivery system or radiopharmaceutical drugs delivery system comprises a status light system that illuminates the working area to enable distance monitoring. Further, the delivery system includes a disposable secondary containment system that protects the core workstation from contamination, a configurable dose transporter and a disposable sealed fluid cartridge to withdraw custom volume from the vial or syringe.

Abstract: The invention is a theranostic delivery system or radiopharmaceutical drugs delivery system with movable workstation having handles. The workstation of theranostic delivery system or radiopharmaceutical drugs delivery system also has an on-board shielded disposal system for waste collection, which is operated by foot actuated system for locked and unlocked modes during the device journey. The theranostic delivery system or radiopharmaceutical drugs delivery system comprises a status light system that illuminates the working area to enable distance monitoring. Further, the delivery system includes a disposable secondary containment system that protects the core workstation from contamination, a configurable dose transporter and a disposable sealed fluid cartridge to withdraw custom volume from the vial or syringe.

Abstract: The invention is a theranostic delivery system or radiopharmaceutical drugs delivery system with movable workstation having handles. The workstation of theranostic delivery system or radiopharmaceutical drugs delivery system also has an on-board shielded disposal system for waste collection, which is operated by foot actuated system for locked and unlocked modes during the device journey. The theranostic delivery system or radiopharmaceutical drugs delivery system comprises a status light system that illuminates the working area to enable distance monitoring. Further, the delivery system includes a disposable secondary containment system that protects the core workstation from contamination, a configurable dose transporter and a disposable sealed fluid cartridge to withdraw custom volume from the vial or syringe.

Abstract: The present invention provides a conjugate compound comprising a nanoparticulated enhanced permeability and retention (EPR) agent, which is an albumin, conjugated with one or more chelating agents, one or more target specific ligands and one or more detectable agents and optionally comprising one or more heterobifunctional crosslinkers and one or more pharmaceutically acceptable therapeutic agents. Further, the present invention provides a radiopharmaceutical composition and a kit comprising the said conjugate and also provides application of the same in diagnosis and therapy of various disease like cancer.